New antibody drug aims to tame Hard-to-Treat kidney disease
NCT ID NCT07234474
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called YK012 in 66 adults with a severe form of kidney disease called primary membranous nephropathy that has not responded to standard treatments. YK012 is a bispecific antibody designed to reduce the immune system's attack on the kidneys. The main goals are to check safety and how the drug behaves in the body, with a preliminary look at whether it might help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YK012 (a bispecific antibody that targets B cells and T cells to reduce immune attack on the kidneys)
What this could lead to
If it works, this could point toward a new treatment option for people with a severe, hard-to-treat kidney disease that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety, not proof of effectiveness. The drug may cause side effects or fail to improve kidney function. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••